/** Title: Concord Biotech Q1 FY27: Export-led growth, margin expansion, and early bets on injectables and the US Slug: q1fy27-update Cover Image Description: An ultra-realistic corporate finance visual showing a clean dashboard on a desk with a laptop and papers. The dashboard includes a bar chart comparing two quarters with revenue rising from 204 to 257.5, a second chart showing exports rising from 83 to 121.7, and margin gauges showing gross margin near 79% and EBITDA margin near 32%. In the background, a subtle industrial biotechnology setting is visible with stainless steel fermentation tanks and a sterile production corridor, all without any logos or text. Short Title: Concord Biotech Q1 FY27 export surge */

Concord Biotech Q1 FY27: Export-led growth, margin expansion, and early bets on injectables and the US

Concord Biotech opened FY27 with a strong first quarter, led by a rebound in customer demand and a sharp acceleration in exports. In Q1 FY27, consolidated revenue from operations rose to Rs 257.5 crore, up 26% year-on-year from Rs 204.0 crore. Profitability improved faster than sales, with EBITDA at Rs 82.4 crore, up 34%, and profit after tax (PAT) at Rs 57.7 crore, up 31%.

The margin story was equally important. Gross margin improved to 78.9% from 77.9%, and EBITDA margin expanded to 32.0% from 30.1%. Management attributed the improvement to pricing discipline, favorable product mix, and limited competitive intensity in key categories. It also disclosed that EBITDA margin would have been 37% in the quarter if one excludes the impact of the injectable facility and Stellon Biotech related expenses. That statement frames the quarter as one where legacy fermentation strengths are carrying the financials, while new growth platforms are still in investment mode.

A quarter driven by APIs and exports

The revenue mix in Q1 FY27 tilted decisively toward APIs. The API segment delivered Rs 218.9 crore versus Rs 153.8 crore in Q1 FY26, a 42% year-on-year increase. Formulations revenue declined to Rs 38.6 crore from Rs 50.2 crore, a 23% decline.

Management repeatedly cautioned investors against treating the API and formulations segments as standalone engines. Concord’s model is positioned as an integrated platform, where opportunities may be served either through APIs or through finished dosage formulations depending on customer requirements and the company’s ability to capture value. The CFO highlighted that segment mix can vary quarter to quarter because the company aims to maximize overall growth and value creation rather than target a fixed mix.

Geographically, export performance stood out. Export revenue increased to Rs 121.7 crore from Rs 83.0 crore, a 46% year-on-year growth. Domestic revenue grew more steadily to Rs 135.8 crore from Rs 121.0 crore, a 12% rise. Management described export growth as broad-based across geographies, supported by rising inquiries from regulated and semi-regulated markets.

This emphasis on regulated-market credibility is not incidental. The company highlighted regulatory inspections completed during the quarter, including ANVISA inspection at the Limbasi API facility and inspections by PPB Kenya and NDA Uganda at the Unit-II formulations facility. These inspections strengthen the company’s ability to supply across geographies and add to its positioning as a globally compliant fermentation player.

Financial snapshot (consolidated)

Why formulations fell and why management is not alarmed

The formulation business is clearly an area where investors will seek more consistency. Q1 FY27 saw a visible decline in formulations revenue. In the Q&A, management offered two explanations.

First, it said that the domestic formulation business in Q1 of the previous year included supplies meant for the Middle East, which did not repeat in the current quarter. Second, it explained that in some situations the company chooses to address an opportunity via the API route rather than through formulations. In such cases, the same demand could show up as API growth even if formulations look soft.

That said, the company’s longer-term strategy continues to involve expanding formulations, especially in injectables, and building a US-facing platform. Management also indicated that it expects around Rs 600 to 700 crore of the longer-term revenue ambition to come from formulations, implying that the segment remains strategically important even if quarterly numbers remain uneven.

The pipeline and regulatory engine remains central

Concord’s core identity remains tied to fermentation-based APIs, with the presentation highlighting a portfolio of 30-plus fermentation APIs, 150-plus drug master files filed globally, and presence in over 70 countries. It also highlighted seven ANDA approvals and 180-plus approved formulation products across markets.

In Q1 FY27, the company received USFDA ANDA approvals for Mycophenolate Mofetil and Tofacitinib tablets. The investor presentation also lists seven ANDA-approved products for regulated markets, including Tacrolimus capsules and Teriflunomide tablets. Management described these approvals as adding a runway for growth, supported by relationships with marquee customers.

On launches, management reiterated its aim to launch two to three products each year. It also said that a couple of products are at advanced stages of development and could be commercialized in the coming quarters. While the company did not quantify the revenue contribution expected from these products, it called out traction in products like Nystatin and highlighted fusidic acid, launched in FY26, as a niche, large-volume product in Europe with limited players.

These details matter because management is also pointing investors to a multi-year capacity-led growth story. In the call, it said the current infrastructure has the potential to support about Rs 3,000 crore of revenue over time, with roughly Rs 2,200 crore expected from APIs and Rs 600 to 700 crore from formulations.

New growth verticals: Stellon Biotech, injectables, and CDMO

Concord’s FY27 narrative is also about building the next layer of growth beyond the core API engine. Three verticals were discussed repeatedly: the injectables facility, Stellon Biotech, and CDMO.

The injectables facility is still in a ramp-up phase. Management said the plant is already commercialized, with exhibit batches completed, batches on stability, and filings underway. It guided that approvals in emerging markets typically take 12 to 15 months and expects sales to those markets to start next year. It also clarified that domestic sales have already started, primarily by shifting some in-house branded products from third-party sourcing to internal manufacturing. Utilization in the quarter was stated at about 5%.

Stellon Biotech is a US front-end distribution platform for formulation products. Management said commercial operations and sales have started, but the business is nascent. It expects Stellon to market Concord products and also in-license third-party products for the US market.

CDMO is positioned as a medium-term lever, especially given Concord’s fermentation expertise. Management said CDMO revenue is currently around 1% to 2% of sales. It also stated an intent to make CDMO a double-digit contributor over time and expects at least one additional CDMO project to commercialize in the current year.

A key subtext across these verticals is that they are not yet contributors at scale. They currently add cost, and management openly acknowledged that reported margins are suppressed by expenses related to injectables and Stellon. At the same time, it framed the next step as operating leverage, where any additional utilization should improve profitability because much of the cost base has already been built.

Capacity, utilization, and capital allocation

Management shared utilization levels for key facilities on the call. Unit 1 API utilization was about 80%, Unit 3 API utilization was around 55%, and Unit 2 formulations utilization was around 25%. It also noted that Unit 3 utilization includes some portion used for key starting materials (KSMs), and that utilization can vary depending on the product mix.

On expansion, management said it would consider adding API capacity at Unit 3 when utilization reaches about 80% to 85%. It also noted that only 20% to 25% of the Unit 3 land has been utilized, implying room for brownfield growth. It added that earlier expansion could also be driven by dedicated capacity needs for adjacencies such as peptides or veterinary products.

The balance sheet remains a cushion. Management stated the company is zero debt and had cash and cash equivalents of more than Rs 442 crore as of 30 June 2026. Quarterly capex was about Rs 9.5 crore. On capital allocation, management said it continues to pay dividends and is also exploring organic and inorganic growth in fermentation adjacencies.

What to track from here

Concord Biotech’s Q1 FY27 performance showed a return to high growth, particularly in exports and APIs, after management described FY26 as a challenging year due to shifts in customer buying patterns, approval delays, and tariff-related uncertainties. The company’s ability to grow revenue by 26% while expanding margins suggests that its niche fermentation positioning continues to offer pricing and scale advantages.

The next questions are about sustainability. Management said some of the quarter’s strength also reflected spillover of delayed procurement patterns, and it expects spillovers to continue. Investors will therefore track whether growth remains broad-based through FY27 without relying on one-off normalization.

Equally important will be progress in the newer verticals. Injectables at 5% utilization and Stellon at an early stage are meaningful levers, but they are also execution-dependent. Management’s own messaging suggests that the path to 40% EBITDA margin depends on ramp-up in these areas, with the timeline leaning toward FY28.

For now, the quarter reinforced a consistent theme: a strong core fermentation business that is throwing off growth and profitability, paired with measured investments aimed at expanding the company’s addressable market over the next few years.